Foghorn Therapeutics (FHTX) News Today $3.97 -0.25 (-5.92%) Closing price 04:00 PM EasternExtended Trading$4.21 +0.24 (+6.15%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR MeetingMarch 25 at 4:35 PM | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from BrokeragesFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendatMarch 22 at 4:11 AM | marketbeat.com2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,029,383 shares of the company's stock, valued at approxMarch 22 at 3:17 AM | marketbeat.comWhat is B. Riley's Forecast for FHTX Q1 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings estimates for Foghorn Therapeutics in a research note issued on Thursday, March 13th. B. Riley analyst K. Patel forecasts that the company will earn ($0.34) per share for tMarch 17, 2025 | marketbeat.comFoghorn Therapeutics' (FHTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Foghorn Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comFoghorn Therapeutics (NASDAQ:FHTX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPSFoghorn Therapeutics (NASDAQ:FHTX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.13.March 7, 2025 | marketbeat.comFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic OutlookMarch 6, 2025 | globenewswire.comInstitutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year lossesFebruary 28, 2025 | finance.yahoo.comFoghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on ThursdayFoghorn Therapeutics (NASDAQ:FHTX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been given an average rating of "Buy" by the six brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, four have issued a buy recommenFebruary 24, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Sees Large Increase in Short InterestFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 918,000 shares, a growth of 9.1% from the January 15th total of 841,700 shares. Based on an average daily volume of 159,900 shares, the days-to-cover ratio is presently 5.7 days. Currently, 3.5% of the shares of the stock are short sold.February 18, 2025 | marketbeat.comWhat is B. Riley's Estimate for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at B. Riley issued their FY2024 earnings per share (EPS) estimates for shares of Foghorn Therapeutics in a report issued on Wednesday, January 29th. B. Riley analyst K. Patel expects that the company will post earnings pFebruary 3, 2025 | marketbeat.comB. Riley Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Strong-Buy"B. Riley raised shares of Foghorn Therapeutics to a "strong-buy" rating in a research report on Wednesday.January 31, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy RecommendationJanuary 30, 2025 | msn.comFoghorn Therapeutics a new buy at B Riley on tumor fighting technologyJanuary 30, 2025 | msn.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Rating of "Moderate Buy" by BrokeragesShares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assignedJanuary 30, 2025 | marketbeat.comB.Riley sets Foghorn stock Buy rating, $10 targetJanuary 30, 2025 | msn.comFoghorn Therapeutics initiated with a Buy at B. RileyJanuary 30, 2025 | markets.businessinsider.comOptimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic DevelopmentsJanuary 30, 2025 | markets.businessinsider.comFoghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. RileyB. Riley began coverage on Foghorn Therapeutics in a research report on Thursday. They issued a "buy" rating and a $10.00 target price for the company.January 30, 2025 | marketbeat.comFoghorn Therapeutics files $300M mixed securities shelfJanuary 25, 2025 | markets.businessinsider.comFoghorn Therapeutics highlights strategic objectives for 2025January 13, 2025 | markets.businessinsider.comFoghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025January 13, 2025 | finance.yahoo.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC lifted its holdings in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 27.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 677,386 shares of the company's stock after buying an additional 146,276 sharesJanuary 4, 2025 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Short Interest UpdateFoghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 948,600 shares, an increase of 6.8% from the November 30th total of 888,000 shares. Approximately 3.4% of the shares of the company are short sold. Based on an average trading volume of 150,800 shares, the days-to-cover ratio is currently 6.3 days.January 2, 2025 | marketbeat.comWedbush Has Pessimistic Outlook of FHTX FY2028 EarningsFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at Wedbush dropped their FY2028 earnings per share estimates for Foghorn Therapeutics in a research report issued to clients and investors on Monday, December 16th. Wedbush analyst R. Driscoll now forecasts that the compDecember 19, 2024 | marketbeat.comFY2024 Earnings Forecast for FHTX Issued By HC WainwrightFoghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Investment analysts at HC Wainwright raised their FY2024 earnings estimates for Foghorn Therapeutics in a note issued to investors on Tuesday, December 17th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings ofDecember 19, 2024 | marketbeat.comFoghorn Therapeutics’ Strategic Shift and Financial Strength Bolster Buy Rating Amid Promising FHD-909 ProspectsDecember 17, 2024 | markets.businessinsider.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 888,000 shares, a drop of 9.7% from the November 15th total of 983,500 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily volume of 155,900 shares, the short-interest ratio is presently 5.7 days.December 17, 2024 | marketbeat.comFoghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $13.00 price objective (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday.December 17, 2024 | marketbeat.comFoghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug DevelopmentDecember 17, 2024 | markets.businessinsider.comJefferies Financial Group Lowers Foghorn Therapeutics (NASDAQ:FHTX) Price Target to $14.00Jefferies Financial Group lowered their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Monday.December 16, 2024 | marketbeat.comFoghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic PrioritiesDecember 16, 2024 | globenewswire.comFoghorn Therapeutics to Participate in Three Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comAnalysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter ReportNovember 7, 2024 | finance.yahoo.comWhat is HC Wainwright's Forecast for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for Foghorn Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now expects that the company will post earNovember 7, 2024 | marketbeat.comWhat is Wedbush's Estimate for FHTX FY2024 Earnings?Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush lifted their FY2024 EPS estimates for shares of Foghorn Therapeutics in a report issued on Monday, November 4th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.57) per share for the yearNovember 7, 2024 | marketbeat.comFoghorn Therapeutics Reports Third Quarter HighlightsNovember 6, 2024 | markets.businessinsider.comOptimistic Buy Rating for Foghorn Therapeutics Amid Promising Phase 1 Study and Strategic Pipeline AdvancementsNovember 6, 2024 | markets.businessinsider.comFoghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate UpdateNovember 4, 2024 | globenewswire.comShort Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1%Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,200,000 shares, an increase of 9.1% from the September 15th total of 1,100,000 shares. Based on an average daily volume of 152,000 shares, the short-interest ratio is presently 7.9 days. Currently, 4.2% of the shares of the stock are sold short.October 17, 2024 | marketbeat.comFoghorn Therapeutics Unveils Clinical Pipeline ProgressOctober 11, 2024 | finance.yahoo.comFoghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid TumorsOctober 10, 2024 | globenewswire.comFoghorn Therapeutics (NASDAQ:FHTX) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comFoghorn Therapeutics (NASDAQ:FHTX) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comFoghorn Therapeutics to Participate in the BMO Oncology SummitOctober 1, 2024 | globenewswire.comPerceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Perceptive Advisors LLC acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 544,000 shares of the company's stock, valueSeptember 30, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX)Deerfield Management Company L.P. Series C acquired a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,518,500 shaSeptember 26, 2024 | marketbeat.comFoghorn Therapeutics Inc. (NASDAQ:FHTX) Insider Sells $358,990.24 in StockSeptember 25, 2024 | insidertrades.com Remove Ads Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address FHTX Media Mentions By Week FHTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FHTX News Sentiment▼1.330.68▲Average Medical News Sentiment FHTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FHTX Articles This Week▼31▲FHTX Articles Average Week Remove Ads Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rocket Pharmaceuticals News Today Xencor News Today Zymeworks News Today Xeris Biopharma News Today Phibro Animal Health News Today Gyre Therapeutics News Today Oculis News Today Replimune Group News Today Cogent Biosciences News Today Day One Biopharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FHTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FHTX Stock Free FHTX Stock Alerts